Acasunlimab

Acasunlimab (GEN1046) is a bispecific antibody (bsAb) targeting PD-L1 and 4-1BB. Acasunlimab enhances T-cell and NK-cell function through conditional 4-1BB stimulation while constitutively blocking the PD-1/PD-L1 inhibitory axis. Acasunlimab can be used in research of cancer[1][2].

Research Areas >> Cancer

Signaling Pathways >> Immunology/Inflammation >> PD-1/PD-L1

Acasunlimab (GEN1046; 0.001-1 μM; 0-525 min) 促进树突状细胞和 T 细胞之间的相互作用并增强 T 细胞活化[1]。 Acasunlimab (0.001-1 μM; 48 h; PD-L1+ Tumor Cells) 在体外诱导剂量依赖性、条件性 T 细胞增殖和细胞因子产生，并增强抗原特异性 T 细胞介导的细胞毒性[1]。

Acasunlimab (5 mg/kg; i.v.; 每周两次，共三个周期) 在双敲入 (dKI) 转基因 C57BL/6 小鼠中具有抗肿瘤活性并抑制肿瘤生长[1]。 Animal Model: Double knock-in (dKI) transgenic C57BL/6 mice[1] Dosage: 5 mg/kg Administration: Intravenous injection; twice weekly for three cycles Result: Had antitumor activity in double knock-in (dKI) transgenic C57BL/6 mice.

[1]. Muik A, et, al. Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors. Cancer Discov. 2022 May 2;12(5):1248-1265.  

[2]. Gao Y, et, al. Development and characterization of a novel human CD137 agonistic antibody with anti-tumor activity and a good safety profile in non-human primates. FEBS Open Bio. 2022 Dec;12(12):2166-2178.